Cesca Therapeutics down 11% premarket after Biotech Showcase presentation

|About: Cesca Therapeutics Inc (KOOL)|By:, SA News Editor

Thinly traded nano cap Cesca Therapeutics (NASDAQ:KOOL) is down 11% premarket on average volume after a presentation yesterday after the close by CEO Chris Xu, Ph.D., at the Biotech Showcase in San Francisco.

Dr. Xu reviewed the history of the company and business strategy saying it will focus on CAR-T co-development arrangements this year. No financial guidance was provided.

Subscribe for full text news in your inbox